CN203144407U - Kit for brain tumor drug sensitivity test - Google Patents
Kit for brain tumor drug sensitivity test Download PDFInfo
- Publication number
- CN203144407U CN203144407U CN 201320160664 CN201320160664U CN203144407U CN 203144407 U CN203144407 U CN 203144407U CN 201320160664 CN201320160664 CN 201320160664 CN 201320160664 U CN201320160664 U CN 201320160664U CN 203144407 U CN203144407 U CN 203144407U
- Authority
- CN
- China
- Prior art keywords
- film
- medicine
- prepackage
- brain tumor
- culture plate
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
Images
Landscapes
- Apparatus Associated With Microorganisms And Enzymes (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Abstract
The utility model provides a kit for brain tumor drug sensitivity test. The kit is composed of a kit body, a drug sensitivity test assembly, a designation card and an instruction book, wherein the drug sensitivity test assembly, the designation card and the instruction book are arranged in the kit body. The kit is characterized in that the drug sensitivity test assembly comprises a brain tumor drug membrane, a blank drug membrane and a cell culture plate, the brain tumor drug membrane, the blank drug membrane and the cell culture plate are pre-installed according to a preset chemotherapy regimen to form a pre-installed culture plate, or the brain tumor drug membrane and the blank drug membrane are packaged individually and form adjustable assorted culture plates together with the cell culture plate. In a brain tumor drug sensitivity test, the kit provided by the utility model not only improves the operation efficiency of the tumor drug sensitivity test and ensures simple and convenient operation, but also greatly improves the accuracy of the drug sensitivity test, greatly reduces the dosage of test drug, lowers the drug cost and improves the economical efficiency of the drug sensitivity test, and the kit is particularly suitable for drug sensitivity test of combined chemotherapy.
Description
Technical field
The utility model relates to a kind of device of antitumor susceptibility test, specifically, relates to a kind of test kit for the detection of brain tumor susceptibility.
Background technology
Malignant tumour is serious harm human life and healthy common disease and frequently-occurring disease, is to cause one of disabled and early dead principal disease, and in 35～59 years old age group, malignant tumour occupies first of the cause of the death.Data shows that sending out case load China's malignant tumour year is 2,000,000, and is dead about 1,500,000, and with 3% speed increase and be rejuvenation trend, occupy mortality ratio in all kinds of diseases.
Intracranial tumors is various cerebral tumors, is one of disease common in the neural system, and human nervous system's function is had very big harm.Generally be divided into former and secondary two big classes.The primary intracranial tumors can betide cerebral tissue, meninx, cranial nerve, hypophysis, the remaining embryonic tissue of blood vessel etc.Secondary tumors refers to that the malignant tumour at other position of health shifts or invade the metastatic tumor that encephalic forms.Cerebral tumor also claims intracranial spaceoccupying lesion.
In recent years, the intracranial tumors sickness rate is in rising trend, according to statistics, intracranial tumors accounts for 5% of general tumour, account for 70% of pediatric tumor, and other malignant tumour finally has 20-30% and changes encephalic over to, because the infiltrative growth of its expansion, when in a single day encephalic occupies certain space, no matter its character is optimum or pernicious, intracranial pressure is raise, the compressing cerebral tissue, cause the nervus centralis infringement, jeopardize patient's life.
Intracranial tumors can betide any age, with 20-50 year for seeing at most.The juvenile is with fossa cranii posterior and the center line tumour is more sees, the adult with the hemicerebrum glioma for seeing at most.Primary intracranial tumors incidence does not have obvious gender difference, and the man is slightly more than the woman.
Glioma is the tumour that originates from neurogliocyte, is modal primary intracranial tumors.In the WHO central nerve neuroma classification glioma being divided into I～IV level, III, IV level is glioblastoma, accounts for 77.5% of all gliomas.Nearly 30 years, primary malignancy cerebral tumor incidence cumulative year after year, annual growth is about 1.2%, and elderly population is particularly evident.
The treatment of glioblastoma is taked based on operative treatment the complex therapy of therapies such as combination with radiotherapeutic, chemotherapy.Temozolomide (TMZ) radiotherapy synchronously associating adjuvant chemotherapy has become the standard scheme of new diagnosis glioblastoma multiforme (GBM).
Unconditionally with the GBM person of TMZ GBM patient is advised Nimustine (ACNU, or other alkanisation class medicine carmustines, semustine).
The anaplastic glioma (WHOIII level) of new diagnosis: recommend radiotherapy associating Temozolomide (isopolymorphism glioblastoma multiforme) or use the scheme that contains the nitrosourea chemotherapeutics: (1) PCV scheme (lomustine+procarbazine+vincristine(VCR)).(2) ACNU scheme.
Although chemotherapy is occupied important status in the treatment of malignant tumour, in clinical practice, the result is often not fully up to expectations.Wherein, it is the common factor that causes the chemotherapy of tumors failure that tumour cell produces resistance to chemotherapeutics, also is the key difficult problem of puzzlement oncotherapy.The resistance problem is very general clinical problem, estimates according to American Cancer Society, and the patient because of tumor mortality more than 90% is being subjected to the resistance influence in varying degrees.
Drug resistance of tumor cell is divided into primary and acquired resistance two big classes.Common way is clinically at present, follow the card result of study according to the test of international clinical tumor, learn that different chemotherapeutics is to different tumor treatment susceptibility differences, be that each tumour has corresponding effective chemotherapy medicament sensitive spectrum, thereby the scheme for combining of selecting the single medicine of the highest chemotherapy of curative effect or multiple medicine to form is treated.But often run into such situation clinically, be known as the effective treatment plan of certain tumour through following card research, and the patient who has is had no effect.Be a kind of medicine with milestone significance as Zorubicin to infiltrative breast carcinoma, but still have 50% infiltrative breast carcinoma patient insensitive to this medicine.And for example be good for and select, the curative effect that brain tumor is generally acknowledged is obvious, but also has the patient's curative effect more than 60% also not obvious.
Tumour exists tangible individual difference to various chemotherapeutics.Be different tumor types or the different patients of same type, even same patient is in the different morbidity stages, to the susceptibility of chemotherapy and incomplete same, the result for the treatment of difference is also very big.So far the combined utilization that does not also have a kind of chemotherapeutics or several chemotherapeutics can be effective to a certain tumour 100%.Clinically, use with a kind of chemotherapeutics or with the different tumour patient of a kind of chemotherapy regimen treatment, obviously have certain blindness.Therefore, carrying out the tumour drug sensitive test at different patients before chemotherapy selects effective chemotherapeutics to carry out chemotherapy to seem very necessary.For this reason, set up a kind ofly as the bacterium sensitization test, by sensitivity testing method relatively reliably, different patients is accurately screened responsive chemotherapeutics, and determine its dosage, really realize clinical personalized medicine.
Tumour drug sensitive test is at present operated required medicine to face with now joining, and the tumour drug sensitive test need be tested multiple antitumor drug, and the soup prepared and diluted is loaded down with trivial details, and the required antitumor drug dosage of tumour drug sensitive test is little, sampling inconvenience.The part drug solution following shelf time of state is short, and remainder can only be scrapped, and causes the waste of medicine, especially expensive medicine.
CN93111551.5 discloses tumour chemotherapy medicament sensitive pretest agent compounding method and test kit, and this patent is pre-installed on 8 kinds of antitumor drugs commonly used in the specimen bottle by setting dosage.But this method is not easy to the test of Combination chemotherapy, and is not easy to the dose titration of scheme.
CN03102260.X adopts the method for prefabricated medicine sensitive detecting plate, and antitumor drug is added in the check-out console by calculating dosage, and freeze-drying, packing are used for the tumour drug sensitive test.This method is not easy to the test of Combination chemotherapy equally, and is not easy to the dose titration of scheme.
Clinical have the method for the interim preparation of a small amount of employing antitumor drug to carry out the antitumor drug antibiotics susceptibility test at present, and still, there are many problems in this method: accurate concentration the unknown of compounding pharmaceutical, and the accuracy of institute's preparating liquid leaves a question open; The antitumor drug antibiotics susceptibility test of clinical oral administration antitumor drug can't carry out; The individual operations error is big.
For the ease of the operation of tumour drug sensitive test and save cost, we will various brain tumor antitumor drugs commonly used be prepared into, and dosage is accurate, good stability, can be in tumor cell culture liquid rapidly-soluble aseptic medicine film.And the medicine film cut into slices packing accurately by using dosage.
The utility model content
The utility model relates to a kind of device of antitumor susceptibility test, specifically, relates to a kind of test kit for the brain tumor antibiotics susceptibility test.
Technical solutions of the utility model are as follows:
The test kit that a kind of brain tumor susceptibility detects, formed by box body, antibiotics susceptibility test assembly, designation card and specification sheets, antibiotics susceptibility test assembly, designation card and specification sheets place in the box, it is characterized in that described antibiotics susceptibility test assembly comprises brain tumor medicine medicine film, blank medicine film and Tissue Culture Plate.
Test kit described above is characterized in that described antibiotics susceptibility test assembly also comprises medicine activating enzymes packing.
Test kit described above is characterized in that in the described antibiotics susceptibility test assembly, and brain tumor medicine medicine film and blank medicine film and Tissue Culture Plate form the prepackage culture plate by setting the chemotherapy regimen prepackage.
Test kit described above is characterized in that in the described antibiotics susceptibility test assembly that brain tumor medicine medicine film and blank medicine film have been formed adjustable suit culture plate with independent packaging and Tissue Culture Plate respectively.
Test kit described above, it is characterized in that described brain tumor medicine medicine film is selected from Temozolomide film, nimustine film, carmustine film, semustine film, lomustine film, Procarbazine film, a kind of or two or more in vincristine(VCR) film, the irinotecan film.
Test kit described above is characterized in that described Tissue Culture Plate is 24 porocyte culture plates.
As preferably, test kit described above is characterized in that described Tissue Culture Plate is 24 porocyte culture plates.
Preferably, test kit described above is characterized in that described prepackage culture plate is the brain tumor medicine sensitive detecting plate, and it is prepackage 24 well culture plates, and the pre-powder charge film in hole is as follows:
The blank medicine film of prepackage in 2 holes
Prepackage Temozolomide film in 2 holes
Prepackage carmustine film in 2 holes
Prepackage Procarbazine film in 2 holes
Prepackage irinotecan film in 2 holes
Prepackage nimustine film in 2 holes
Prepackage semustine film in 2 holes
Prepackage lomustine film, procarbazine film and vincristine(VCR) film in 2 holes
8 Kong Zhongwu medicine films.
The utility model is a kind of test kit for the test of the antitumor susceptibility of brain tumor, and susceptibility test suite packaged form be by two kinds of the prepackage culture plate of setting the chemotherapy regimen prepackage and adjustable suits that independently the medicine film is packed and blank 24 porocyte culture plates make up with brain tumor medicine medicine film and 24 porocyte culture plates in the test kit.
Contain a brain tumor antitumor drug medicine film packing box, a Tissue Culture Plate commonly used in each adjustable suit.The code name of each medicine film is arranged on the medicine film packing, and each Tissue Culture Plate attaches a designation card, is used for the pharmaceutical cpd in each hole of mark.
Various antitumour drug films and blank medicine film place independently aseptic the lid in the small plastic box respectively, in the big plastics casing of again small plastic box being packed in order.Various medicine activating enzymes place independently aseptic the lid in the small plastic box respectively, in the big plastics casing of again small plastic box being packed in order.
Tissue Culture Plate is 24 porocyte culture plates, and designation card is 24 lattice, is used for the pharmaceutical cpd in each hole of mark.
During use, blank, the contrast of blank medicine film and various chemotherapy regimen are marked on respectively on the designation card, press the designation card content and add the medicine film in Tissue Culture Plate, add the tumour cell suspension, vibration makes medicine film dissolving mixing.
The chemotherapy regimen that the prepackage culture plate sets is worked out with reference to the standard chemotherapy regimen of up-to-date practice guidelines.By the setting scheme medicine film is packed in each hole of culture plate.
Medicine medicine film described in the utility model, normally, medicine medicine film contains 0.0001%～30% antitumor drug, 50%～98% film forming material and 1%～20% softening agent by weight percentage.Wherein, described film forming material includes but not limited to polyvinyl alcohol, hypromellose, hydroxypropylcellulose, Xylo-Mucine, polyvinylpyrrolidone, polyethylene amine, polyethylene amido-acetal derivative, polyvinyl pyridine derivative, gelatin, gum arabic, shellac, agar, Lalgine and salt thereof, zein, starch, dextrin, bletilla striata glue etc.Preferred polyvinyl alcohol 04-88 and the polyvinyl alcohol 05-88 of using.Described softening agent is selected from glycerine, polyoxyethylene glycol, ethylene glycol, propylene glycol, sorbyl alcohol, triethyl citrate etc.
Medicine medicine film described in the utility model can prepare with ordinary method in this area, for example can make brain tumor medicine medicine film as follows:
(1) film forming material is added to the water stirring and dissolving or heating for dissolving;
(2) add softening agent and antitumor drug, stirring and dissolving is even, adopts heating, leaves standstill or mode such as ultrasonic outgases;
(3) with above-mentioned solution coat in membrane equipment, adopt mode dryings such as hot blast or cold wind;
(4) demoulding is measured content, and carries out divided dose according to measurement result and cut apart;
(5) the medicine film after will cutting apart adopts radiation exposure sterilization or ethylene oxide sterilizing, preferred radiation exposure sterilization.
The plasma peak concentration preparation of various tumor chemotherapeutic drug medicine film reference drugs in human body according to medicine film assay result, is cut into the chemotherapeutics that contains the 1ml plasma peak concentration with every medicine film, blank medicine film cutting area 1cm
2
For the ease of the operation of tumour antibiotics susceptibility test, the medicine film needs and can be dissolved in fast in the tumor cell culture liquid.Therefore film forming material will be easy to dissolving, and the thickness of film and area will be controlled in suitable scope, guarantees dissolution rate and physical strength.Preferred 0.04mm～the 0.15mm of thickness.Shape can be circle, square or rectangular, and area is preferably 0.5cm
2～16cm
2, to adapt to the Tissue Culture Plate of corresponding specification.1cm of the present invention
2The film of size can dissolving in 100 seconds in the 1ml nutrient solution.
Described blank medicine film refers to not contain the medicine film of brain tumor medicine, can be prepared according to above-mentioned brain tumor medicine medicine membrane method, but not add the brain tumor medicine.
The utility model is in carrying out the brain tumor antibiotics susceptibility test, not only improve the operation efficiency of tumour antibiotics susceptibility test, make easy and simple to handle, and improved the accuracy of antibiotics susceptibility test greatly, significantly reduce the testing drug consumption, save drug cost, improve the economy of antibiotics susceptibility test, particularly, also be applicable to the antibiotics susceptibility test of combined chemotherapy.
Description of drawings
The brain tumor susceptibility detects prepackage 24 well culture plate vertical views in Fig. 1: embodiment 1 utility model;
The brain tumor susceptibility detects prepackage 24 well culture plate plan views in Fig. 2: embodiment 1 utility model;
Designation card in Fig. 3: embodiment 1 utility model.
Wherein:
Among Fig. 1,2, A-D is the hole row number of culture plate, and 1-6 is the hole row number of culture plate, and the combination of the row of hole correspondence number and row number is the numbering in hole, and for example: A6 represents in the hole hole of capable the 6th row of the A of culture plate.
Among Fig. 3, every lattice numbering in the designation card is corresponding to the hole numbering of culture plate.
In each hole of culture plate, pre-powder charge film is as follows:
A1-A2 blank (no medicine film, blank)
The blank medicine film of A3-A4 (the medicine film does not contain medicine, blank medicine film contrast)
A5-A6 Temozolomide film
B1-B2 carmustine film
B3-B4 Procarbazine film
B5-B6 irinotecan film
C1-C2 nimustine film
C3-C4 semustine film
C5-C6 lomustine film, procarbazine film and vincristine(VCR) film
The D1-D6 blank, no medicine film.
Embodiment
Embodiment 1: be used for brain tumor medicine susceptibility detection kit
The utility model test kit detects prepackage 24 well culture plates (Fig. 1,2), designation card (Fig. 3) and specification sheets by box body, brain tumor susceptibility and forms.The brain tumor antibiotics susceptibility test is pre-installed 24 well culture plates, designation card and specification sheets and is placed box.Specification sheets is explanation and introduces test kit, is convenient to the user and correctly uses this test kit.
Before chemotherapy, get brain tumor flesh tissue piece (0.5～1cm of 1 routine patient
3), place stroke-physiological saline solution (containing 200,000 units/ml penicillin, 250,000 units/ml Streptomycin sulphate), on Bechtop, wipe out healthy tissuess such as fat, fiber, and downright bad and blood stains tissue, totally organize with being with antibiotic normal saline flushing, add tissue digestion enzyme (pancreatin, the collagenase) 2～3h that disappears, make tissue block become individual cells and leaked copper mesh, the centrifugal supernatant of abandoning, add the RPMI1640 nutrient solution and blow and beat into cell suspension, counting is also transferred cell concn to 1 * 10
6/ ml.
The cell suspension kind is in prepackage 24 well culture plates (Fig. 1 or 2) (1ml/ hole), and vibration makes medicine film dissolving mixing, and in designation card (Fig. 3) record.37 ℃, 5% carbonic acid gas saturated humidity were cultivated 24 hours.Centrifugal collection suspension cell, Eppendorf centrifuge rotating speed 2000RPM, centrifugation time 5min abandons substratum.With twice of cold PBS washed cell (2000RPM, centrifugation time 5min collecting cell).With 400 μ l1X Binding Buffer suspension cells, concentration is approximately 1 * 10
6/ ml.In cell suspending liquid, add 5 μ lAnnexinV-FITC, under 2-8 ℃ of lucifuge condition, hatched 15 minutes behind the mixing gently.Adding behind the 10 μ l PI gently mixing hatched 5 minutes under 2-8 ℃ of lucifuge condition.In 1 hour, detect control group and medicine group apoptosis and downright bad quantity with flow cytometer, calculate the inhibiting rate of medicine, the susceptibility of assessment medicine.The results are shown in Table 1.
Table 1 is for the inhibiting rate of screening chemotherapy regimen
| Medicine | Inhibiting rate (%) |
| The Temozolomide film | 41 |
| The carmustine film | 56 |
| The Procarbazine film | 27 |
| The irinotecan film | 26 |
| The nimustine film | 50 |
| The semustine film | 42 |
| Lomustine film+procarbazine film+vincristine(VCR) film | 61 |
(inhibiting rate=((blank medicine film control group viable cell-experimental group viable cell)/blank medicine film control group viable cell) * 100%).
Claims (7)
1. one kind is used for the test kit that the brain tumor susceptibility detects, formed by box body, antibiotics susceptibility test assembly, designation card and specification sheets, antibiotics susceptibility test assembly, designation card and specification sheets place in the box, it is characterized in that described antibiotics susceptibility test assembly comprises brain tumor medicine medicine film, blank medicine film and Tissue Culture Plate.
2. test kit according to claim 1, if desired, described antibiotics susceptibility test assembly also can comprise medicine activating enzymes packing.
3. test kit according to claim 1 is characterized in that in the described antibiotics susceptibility test assembly, and brain tumor medicine medicine film and blank medicine film and Tissue Culture Plate form the prepackage culture plate by setting the chemotherapy regimen prepackage.
4. test kit according to claim 1 is characterized in that in the described antibiotics susceptibility test assembly, and brain tumor medicine medicine film and blank medicine film have been formed adjustable suit culture plate with independent packaging and Tissue Culture Plate respectively.
5. according to each described test kit of claim 1-4, it is characterized in that described brain tumor medicine medicine film is selected from Temozolomide film, nimustine film, carmustine film, semustine film, lomustine film, Procarbazine film, a kind of or two or more in vincristine(VCR) film, the irinotecan film.
6. according to each described test kit of claim 1-4, it is characterized in that described Tissue Culture Plate is 24 porocyte culture plates.
7. test kit according to claim 3 is characterized in that described prepackage culture plate is the brain tumor medicine sensitive detecting plate, and it is prepackage 24 well culture plates, and the pre-powder charge film in hole is as follows:
The blank medicine film of prepackage in 2 holes
Prepackage Temozolomide film in 2 holes
Prepackage carmustine film in 2 holes
Prepackage Procarbazine film in 2 holes
Prepackage irinotecan film in 2 holes
Prepackage nimustine film in 2 holes
Prepackage semustine film in 2 holes
Prepackage lomustine film, procarbazine film and vincristine(VCR) film in 2 holes
8 Kong Zhongwu medicine films.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 201320160664 CN203144407U (en) | 2013-03-26 | 2013-03-26 | Kit for brain tumor drug sensitivity test |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 201320160664 CN203144407U (en) | 2013-03-26 | 2013-03-26 | Kit for brain tumor drug sensitivity test |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN203144407U true CN203144407U (en) | 2013-08-21 |
Family
ID=48971950
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN 201320160664 Expired - Fee Related CN203144407U (en) | 2013-03-26 | 2013-03-26 | Kit for brain tumor drug sensitivity test |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN203144407U (en) |
-
2013
- 2013-03-26 CN CN 201320160664 patent/CN203144407U/en not_active Expired - Fee Related
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN101805763A (en) | Inonotus obliquus extracellular and intracellular mixing crude polysaccharide with function of strengthening immunity | |
| CN106890330A (en) | DC CIK cells and the antibody compositions of anti-PD 1 and application thereof | |
| Podolska et al. | Graphene-induced hyperthermia (GIHT) combined with radiotherapy fosters immunogenic cell death | |
| CN107249587A (en) | Antihistamine for treating breast cancer | |
| CN203144407U (en) | Kit for brain tumor drug sensitivity test | |
| CN203144399U (en) | Kit for colorectal cancer susceptibility detection | |
| CN101991579A (en) | Use of ursolic acid as colon tumor resistant medicament | |
| CN203144410U (en) | Kit for breast cancer drug sensitivity test | |
| CN103251585A (en) | Effects and application of artemisinin and its derivative in inhibition of platelet-derived growth factor receptor A | |
| CN203144401U (en) | Kit for ovarian cancer drug sensitivity test | |
| CN203144404U (en) | Kit for cervical cancer susceptibility detection | |
| CN203144409U (en) | Kit for esophagus cancer drug sensitivity test | |
| CN203144403U (en) | Kit for detecting drug sensitivity of pancreatic cancer | |
| CN203144408U (en) | Kit for gastric cancer drug sensitivity test | |
| CN104490942B (en) | Phellinus igniarius (L. ex Fr.) Quel. is as the application of tumor | |
| CN203144405U (en) | Kit for lung cancer susceptibility detection | |
| CN203144411U (en) | Kit for prostatic cancer drug sensitivity test | |
| CN107537027A (en) | TNFSF15 albumen is preparing the purposes in treating melanoma medicine | |
| CN203144400U (en) | Kit for acute leukemia susceptibility detection | |
| CN203144406U (en) | Kit for liver cancer susceptibility detection | |
| Koella et al. | In vitro resistance patterns of Plasmodium falciparum to chloroquine—a reflection of strain-specific immunity? | |
| CN103239436A (en) | Application of isorhamnetin to preparing drugs for adriamycin adjuvant therapy | |
| CN106860450B (en) | The application of hirsutine | |
| CN106957799A (en) | A kind of device for the accurate treatment method of tumour based on CTC circulating tumor cells | |
| CN105769855B (en) | Meroterpenoids compound D1399 is preparing the application in anti-breast cancer medicines |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| C41 | Transfer of patent application or patent right or utility model | ||
| TR01 | Transfer of patent right |
Effective date of registration: 20161018 Address after: 215007 No. 85 East Main Street, Jiangsu, Suzhou Patentee after: Suzhou innovac Medical Technology Consulting Co. Ltd. Address before: Xinghu street Suzhou Industrial Park in Jiangsu province 215125 No. 218 BioBAY A2 building room 330A Patentee before: Suzhou MacWell Biological Medicine Science and Technology Co., Ltd. |
|
| CF01 | Termination of patent right due to non-payment of annual fee | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20130821 Termination date: 20180326 |